Last reviewed · How we verify
Platelet Antiaggregant
At a glance
| Generic name | Platelet Antiaggregant |
|---|---|
| Also known as | Clopidogrel, Acetylsalicylic acid |
| Sponsor | Jaime Daniel Mondragon |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease (PHASE1, PHASE2)
- Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (PHASE3)
- Endovascular Treatment for Mild Stroke With Acute Anterior Circulation Large Vessel Occlusion (NA)
- Chaigui Longmu Ejiao Paste for Ischemic Heart Disease (PHASE2)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant (PHASE4)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- Tanhuo Decoction for Acute Coronary Syndrome With Cerebral Atherosclerosis in Elderly Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Platelet Antiaggregant CI brief — competitive landscape report
- Platelet Antiaggregant updates RSS · CI watch RSS
- Jaime Daniel Mondragon portfolio CI